Statement Of Cash Flows

OncoTherapy Science, Inc. - Filing #7253509

Concept	2024-04-01 to 2025-03-31	As at 2025-03-31	2024-04-01 to 2025-03-31	2023-04-01 to 2024-03-31	As at 2024-03-31	2023-04-01 to 2024-03-31	As at 2023-03-31
Statement of cash flows
Statement of cash flows
Cash flows from operating activities
Profit (loss) before income taxes	-813,992,000 JPY	—	-813,125,000 JPY	-1,285,713,000 JPY	—	-1,006,572,000 JPY	—
Interest expenses	—	—	1,201,000 JPY	218,000 JPY	—	—	—
Decrease (increase) in inventories	—	—	-4,870,000 JPY	25,618,000 JPY	—	—	—
Subtotal	—	—	-811,284,000 JPY	-1,225,319,000 JPY	—	—	—
Interest paid	—	—	-1,311,000 JPY	-109,000 JPY	—	—	—
Income taxes paid	—	—	-2,425,000 JPY	-2,561,000 JPY	—	—	—
Cash flows from operating activities
Increase (decrease) in accounts payable - other	—	—	21,898,000 JPY	-92,161,000 JPY	—	—	—
Other, net	—	—	-20,500,000 JPY	-16,233,000 JPY	—	—	—
Cash flows from operating activities
Impairment losses	—	—	279,000 JPY	154,564,000 JPY	—	—	—
Decrease (increase) in trade receivables	—	—	-63,233,000 JPY	87,484,000 JPY	—	—	—
Net cash provided by (used in) operating activities	—	—	-815,021,000 JPY	-1,227,990,000 JPY	—	—	—
Cash flows from investing activities
Purchase of property, plant and equipment	—	—	-279,000 JPY	-2,627,000 JPY	—	—	—
Net cash provided by (used in) investing activities	—	—	-279,000 JPY	-33,354,000 JPY	—	—	—
Cash flows from facilities maintenance and investing activities
Cash flows from financing activities
Proceeds from issuance of shares	—	—	1,174,772,000 JPY	682,552,000 JPY	—	—	—
Net cash provided by (used in) financing activities	—	—	1,121,527,000 JPY	671,365,000 JPY	—	—	—
Other, net	—	—	-1,000 JPY	-2,000 JPY	—	—	—
Net increase (decrease) in cash and cash equivalents	—	—	306,227,000 JPY	-589,978,000 JPY	—	—	—
Cash and cash equivalents	—	833,883,000 JPY	—	—	527,656,000 JPY	—	1,117,635,000 JPY